Advance Search
LU Yang, GENG Ping. Advances in the treatment of methicillin-sensitive Staphylococcus aureus bloodstream infections[J]. Journal of Clinical Medicine in Practice, 2025, 29(3): 128-132. DOI: 10.7619/jcmp.20243636
Citation: LU Yang, GENG Ping. Advances in the treatment of methicillin-sensitive Staphylococcus aureus bloodstream infections[J]. Journal of Clinical Medicine in Practice, 2025, 29(3): 128-132. DOI: 10.7619/jcmp.20243636
shu

Advances in the treatment of methicillin-sensitive Staphylococcus aureus bloodstream infections

  • Department of Emergency Medicine, the Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, 225001

More Information
  • Received Date: August 18, 2024
  • Revised Date: October 27, 2024
    Graphical Abstract
    • Abstract

  • Methicillin-sensitive Staphylococcus aureus (MSSA) bloodstream infections are associated with high mortality rates. This study reviewed the current epidemiological status, pathogenic mechanisms, risk factors for infection, and novel treatment strategies for MSSA, providing a reference for early treatment of bloodstream infections.

    • FullText(HTML)
    • References (50)
  • [1]
    DEURENBERG R H, VINK C, KALENIC S, et al. The molecular evolution of methicillin-resistant Staphylococcus aureus [J]. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2007, 13(3): 222-235. doi: 10.1111/j.1469-0691.2006.01573.x
    [2]
    DAVID M Z, DAUM R S. Treatment of Staphylococcus aureus infections[J]. Curr Top Microbiol Immunol, 2017, 409: 325-383.
    [3]
    LAMY B, SUNDQVIST M, IDELEVICH E A. Bloodstream infections–Standard and progress in pathogen diagnostics[J]. Clin Microbiol Infect, 2020, 26(2): 142-150. doi: 10.1016/j.cmi.2019.11.017
    [4]
    LAUPLAND K, LYYTIKÄINEN O, SØGAARD M, et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study [J]. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, 2022.
    [5]
    谭艳, 傅建国, 岳蓓. 成人耐甲氧西林金黄色葡萄球菌感染的临床特征和耐药性分析[J]. 中国现代医生, 2021, 59(13): 111-114.
    [6]
    BARBER M. Methicillin-resistant staphylococci[J]. J Clin Pathol, 1961, 14(4): 385-393. doi: 10.1136/jcp.14.4.385
    [7]
    WHITBY M, MCLAWS M L, BERRY G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis[J]. Med J Aust, 2001, 175(5): 264-267. doi: 10.5694/j.1326-5377.2001.tb143562.x
    [8]
    HURLEY J C. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis[J]. Med J Aust, 2002, 176(4): 188-189. doi: 10.5694/j.1326-5377.2002.tb04355.x
    [9]
    KOURTIS A P, HATFIELD K, BAGGS J, et al. Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections-United States[J]. MMWR Morb Mortal Wkly Rep, 2019, 68(9): 214-219. doi: 10.15585/mmwr.mm6809e1
    [10]
    KAVANAGH K T. Control of MSSA and MRSA in the United States: protocols, policies, risk adjustment and excuses[J]. Antimicrob Resist Infect Control, 2019, 8: 103. doi: 10.1186/s13756-019-0550-2
    [11]
    JACKSON K A, GOKHALE R H, NADLE J, et al. Public health importance of invasive methicillin-sensitive Staphylococcus aureus infections: surveillance in 8 US counties, 2016[J]. Clin Infect Dis, 2020, 70(6): 1021-1028. doi: 10.1093/cid/ciz323
    [12]
    KLEIN E Y, ZHU X, PETERSEN M, et al. Methicillin-resistant and methicillin-sensitive Staphylococcus aureus hospitalizations: national inpatient sample, 2016—2019[J]. Open Forum Infect Dis, 2022, 9(1): 585. doi: 10.1093/ofid/ofab585
    [13]
    HORVÁTH A, DOBAY O, SAHIN-TÓTH J, et al. Characterisation of antibiotic resistance, virulence, clonality and mortality in MRSA and MSSA bloodstream infections at a tertiary-level hospital in Hungary: a 6-year retrospective study[J]. Ann Clin Microbiol Antimicrob, 2020, 19(1): 17. doi: 10.1186/s12941-020-00357-z
    [14]
    隋新霞, 冯霞, 邵春红, 等. 血流感染金黄色葡萄球菌分子生物学特征[J]. 中华医院感染学杂志, 2022, 32(10): 1459-1463.
    [15]
    王红, 郁洁, 王博, 等. 住院新生儿鼻腔和体表定植金黄色葡萄球菌的分子特征及耐药性[J]. 中国循证儿科杂志, 2021, 16(5): 379-383.
    [16]
    SAUGET M, BOUILLER K, RICHARD M, et al. Increasing incidence of bloodstream infections due to Staphylococcus aureus clonal complex 398 in a French hospital between 2010 and 2017[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(11): 2127-2132. doi: 10.1007/s10096-019-03653-5
    [17]
    YUAN W C, LIU J H, ZHAN Y C, et al. Molecular typing revealed the emergence of pvl-positive sequence type 22 methicillin-susceptible Staphylococcus aureus in Urumqi, Northwestern China[J]. Infect Drug Resist, 2019, 12: 1719-1728. doi: 10.2147/IDR.S202906
    [18]
    郭秋菊, 冯安平, 陈开明, 等. 金黄色葡萄球菌生物膜形成过程的研究进展[J]. 中国当代医药, 2020, 27(25): 23-26.
    [19]
    DERAKHSHAN S, NAVIDINIA M, HAGHI F. Antibiotic susceptibility of human-associated Staphylococcus aureus and its relation to agr typing, virulence genes, and biofilm formation[J]. BMC Infect Dis, 2021, 21(1): 627. doi: 10.1186/s12879-021-06307-0
    [20]
    郑杨, 查何. 金黄色葡萄球菌生物膜防治研究进展[J]. 中国医药导报, 2021, 18(18): 32-35.
    [21]
    GU F F, HE W P, ZHU D D, et al. Genome-wide comparative analysis of CC1 Staphylococcus aureus between colonization and infection[J]. Eur J Med Res, 2024, 29(1): 474. doi: 10.1186/s40001-024-02076-z
    [22]
    聂志妍, 陈旭, 周红, 等. 上海地区859名青少年鼻腔金黄色葡萄球菌携带及耐药状况调查[J]. 检验医学, 2015, 30(2): 156-159.
    [23]
    董秀慧, 范玉, 张树元, 等. 皮肤软组织感染分离的甲氧西林敏感金黄色葡萄球菌TSST-1基因及耐药性[J]. 中华医院感染学杂志, 2020, 30(16): 2498-2501.
    [24]
    BERUBE B J, WARDENBURG J B. Staphylococcus aureus α-toxin: nearly a century of intrigue[J]. Toxins, 2013, 5(6): 1140-1166. doi: 10.3390/toxins5061140
    [25]
    MCREYNOLDS A K G, PAGELLA E A, RIDDER M J, et al. YjbH contributes to Staphylococcus aureus skin pathology and immune response through Agr-mediated α-toxin regulation[J]. Virulence, 2024, 15(1): 2399798. doi: 10.1080/21505594.2024.2399798
    [26]
    MCCORMICK J K, YARWOOD J M, SCHLIEVERT P M. Toxic shock syndrome and bacterial superantigens: an update[J]. Annu Rev Microbiol, 2001, 55: 77-104. doi: 10.1146/annurev.micro.55.1.77
    [27]
    XU Z, CHEN J Z, VOUGAS K, et al. Comparative proteomic profiling of methicillin-susceptible and resistant Staphylococcus aureus[J]. Proteomics, 2020, 20(2): e1900221.
    [28]
    卯建, 任玉吉, 单斌, 等. 成人金黄色葡萄球菌血流感染133例的危险因素及预后分析[J]. 中国感染与化疗杂志, 2019, 19(4): 345-350.
    [29]
    苏建伟, 钟婉平, 黄国宾, 等. 糖肽类药物治疗甲氧西林敏感金黄色葡萄球菌血流感染的临床特点及预后分析[J]. 分子诊断与治疗杂志, 2022, 14(11): 1976-1980.
    [30]
    罗曼, 刘倩. 食源性金黄色葡萄球菌耐药机制分析[J]. 中国病原生物学杂志, 2022, 17(6): 685-688.
    [31]
    SULLIVAN S B, AUSTIN E D, STUMP S, et al. Reduced vancomycin susceptibility of methicillin-susceptible Staphylococcus aureus has No significant impact on mortality but results in an increase in complicated infection[J]. Antimicrob Agents Chemother, 2017, 61(7): e00316-17.
    [32]
    CHAMBERS H F, FOWLER V G Jr. Intertwining clonality and resistance: Staphylococcus aureus in the antibiotic era[J]. J Clin Invest, 2024, 134(19): e185824.
    [33]
    杨帆. 《抗菌药物临床应用指导原则(2015年版)》解读[J]. 中华临床感染病杂志, 2016, 9(5): 390-393.
    [34]
    中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核和呼吸杂志, 2016, 39(4): 253-279.
    [35]
    COREY G R. Staphylococcus aureus Bloodstream infections: definitions and treatment[J]. Clin Infect Dis, 2009, 48(s4): S254-S259.
    [36]
    ULLOA E R, SINGH K V, GERIAK M, et al. Cefazolin and ertapenem salvage therapy rapidly clears persistent methicillin-susceptible Staphylococcus aureus bacteremia[J]. Clin Infect Dis, 2020, 71(6): 1413-1418.
    [37]
    额尔德木图, 王艳艳, 吕莹莹, 等. 杀白细胞毒素基因阴性金黄色葡萄球菌的基因分型、耐药性及其生物学特征[J]. 吉林大学学报: 医学版, 2022, 48(4): 971-978.
    [38]
    CHANG J, LEE R E, LEE W. A pursuit of Staphylococcus aureus continues: a role of persister cells[J]. Arch Pharm Res, 2020, 43(6): 630-638.
    [39]
    FORD C A, HURFORD I M, CASSAT J E. Antivirulence strategies for the treatment of Staphylococcus aureus infections: a mini review[J]. Front Microbiol, 2020, 11: 632706.
    [40]
    AHMAD-MANSOUR N, LOUBET P, POUGET C, et al. Staphylococcus aureus toxins: an update on their pathogenic properties and potential treatments[J]. Toxins, 2021, 13(10): 677.
    [41]
    FRANÇOIS B, JAFRI H S, CHASTRE J, et al. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial[J]. 2021, 21(9): 1313-1323.
    [42]
    DROZDOWSKI B, ZHOU Y H, KLINE B, et al. Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B[J]. J Immune Based Ther Vaccines, 2010, 8: 9.
    [43]
    时东彦, 李仲兴. 31种中药体外抑制金黄色葡萄球菌的活性研究[J]. 医药导报, 2006, 25(8): 775-777.
    [44]
    田应彪, 陈泽慧, 杨名慧, 等. 16种中药水煎液对MRSA和MSSA体外抑菌试验观察[J]. 中国医院药学杂志, 2009, 29(11): 897-899.
    [45]
    简永欢, 曾婷婷, 林润娴, 等. 巴西苏木素对甲氧西林敏感金黄色葡萄球菌抑制作用机制研究[J]. 国际检验医学杂志, 2023, 44(2): 160-165, 171.
    [46]
    NI W T, TANG H G, SUN C H, et al. Inhibitory effect of jingfang mixture on Staphylococcus aureus α-hemolysin[J]. World J Microbiol Biotechnol, 2024, 40(9): 286.
    [47]
    谷晓雨, 李会, 张佩, 等. 蒲公英、金银花水提剂及颗粒剂对4种致病菌的抑菌作用[J]. 临床合理用药, 2023, 16(1): 5-8.
    [48]
    易雪丽, 陈晓颖, 韦家柱, 等. 金银花对金黄色葡萄球菌体外抑菌作用研究[J]. 右江民族医学院学报, 2024, 46(1): 48-51.
    [49]
    任涛, 庞玉莲, 薛诗夏, 等. 3种金银花提取物抗细菌内毒素的作用研究[J]. 现代农业科技, 2022(18): 150-154.
    [50]
    王大胜, 王大新, 耿平. 成人血流感染金黄色葡萄球菌的临床分布及耐药性分析[J]. 实用临床医药杂志, 2018, 22(1): 1-3. doi: 10.7619/jcmp.201801001
    • Related Articles

  • Related Articles

    [1]TIAN Xueqin, WANG Jiahao, JI Linling, ZHAO Gege, JIANG Jing, WANG Yingge. Correlations of plasma cyclin-dependent kinase 9 level with disease progression and prognosis in patients with acute large artery atherosclerotic cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 6-12. DOI: 10.7619/jcmp.20243593
    [2]BAO Qingying, ZHANG Lingling, MA Songhua, CHEN Xiaobo, JIANG Zhi, JIANG Qiqun. Correlations between serum soluble growth stimulationgene 2 protein, brain natriuretic peptide and the degree of carotid atherosclerosis in patients with acute ischemic stroke[J]. Journal of Clinical Medicine in Practice, 2024, 28(8): 70-74, 78. DOI: 10.7619/jcmp.20240200
    [3]ZHANG Benyin, LU Wuzhang, YANG Jing. Relationships of National Institutes of Health Stroke Scale score, plasma homocysteine level with acute cerebral infarction and analysis in related risk factors[J]. Journal of Clinical Medicine in Practice, 2021, 25(22): 102-105. DOI: 10.7619/jcmp.20212001
    [4]CAO Lan, TAO Yujian, ZHAO Yuanlu, ZHANG Pan. Analysis in risk factors of solitary pulmonary nodules[J]. Journal of Clinical Medicine in Practice, 2021, 25(1): 38-40, 44. DOI: 10.7619/jcmp.20200457
    [5]YANG Li, SUN Xiaohui, HE Jing, WU Yuliang. Influence of trimetazidine combined with clopidogrelon carotid atherosclerotic plaques and inflammatory factors of patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2019, 23(11): 20-23. DOI: 10.7619/jcmp.201911006
    [6]CHENG Liqun. Correlation between leukoaraiosis and cerebral infarction and risk factors[J]. Journal of Clinical Medicine in Practice, 2018, (7): 42-44. DOI: 10.7619/jcmp.201807011
    [7]SHI Guiwen. Risk factors of type 2 diabetes mellitus complicated with carotid atherosclerosis and analysis of neutrophil to lymphocyte ratio and platelets to lymphocyte ratio levels[J]. Journal of Clinical Medicine in Practice, 2018, (1): 27-30. DOI: 10.7619/jcmp.201801009
    [8]CHU Jie, DU Ping, HE Chen, WANG Fangbing, HAO Yingping. Value of apolipoprotein B/A-1 ratio combined with carotid plaque nature examination in predicting the risk of patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2017, (11): 35-37. DOI: 10.7619/jcmp.201711011
    [9]ZHANG Jifang. Research on occurrence of macrosomia and its related risk factors[J]. Journal of Clinical Medicine in Practice, 2014, (3): 116-118. DOI: 10.7619/jcmp.201403041
    [10]WEI Shiyou, WANG Yanlin. Study on risk factors for relapse of stroke in young people[J]. Journal of Clinical Medicine in Practice, 2013, (17): 16-19. DOI: 10.7619/jcmp.201317005

  • Cited by

    Periodical cited type(7)

    1. 张焕. 急性脑梗死患者凝血功能与颈动脉颅外段狭窄及斑块的关系. 吉林医学. 2025(02): 296-300 .
    2. 李桂芳，张菊莲，徐小冬，张容. 急性脑梗死联合轻微脑出血患者的危险因素及对心脑血管事件发生率的影响. 中国急救复苏与灾害医学杂志. 2024(02): 187-190 .
    3. 吕志坤，魏萌萌，李国珍，唐彦，卢波，黄黎明，王海虹，贾磊华. 动态动脉硬化指数联合血清肿瘤坏死因子受体相关因子6、前蛋白转化酶枯草溶菌素9对急性分水岭脑梗死病人的预后价值. 安徽医药. 2024(07): 1363-1368 .
    4. 冯艳，罗文平，张明明，佘林聪，王家欣，孙涌鑫，陈昊青，张薇. 前蛋白转化酶枯草溶菌素-kexin 9型抑制剂对血管内皮的保护作用机制研究进展. 实用临床医药杂志. 2024(15): 142-148 . 本站查看
    5. 陈桂林. 急性脑梗死患者颈动脉斑块危险因素分析. 医药前沿. 2024(09): 36-38 .
    6. 符美茵，燕香菊，崔晓娟，郑东. 超声联合血清前蛋白转化酶枯草溶菌素9、五聚素3检测对下肢动脉硬化闭塞症患者动脉狭窄程度的评估价值. 心脑血管病防治. 2024(12): 62-65 .
    7. 刘景祎，李富慧，张丽，宋彦. 血清IL-17、Sortilin及PCSK9水平与老年脑梗死患者颈动脉硬化的关系研究. 中国卫生检验杂志. 2023(18): 2241-2244 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by(7)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return